San Diego, CA--July 26, 2011--Mentor Capital, Inc. (OTC Markets: MNTR) announces that it is seeking to partner with medical funding entities to accommodate the accelerated progress of its neutron cancer therapy investee, Hadron Systems, Inc. The recent early finalization of a neutron device has jumped the current valuation of Hadron by an estimated 400%, according to discussions with their management.

Mentor Capital’s program plan projected that a neutron device would be developed by February 2012, and Mentor would fund $5 Million spread over that time period. Hadron’s unexpected technical news that it has now cleared that last major hurdle multiplies the value of Mentor’s 9% position, but also will greatly shorten the period for the company to complete the $5 Million in funding. “We look to partner with others to fund timely and maintain our valuable contract rights for the benefit of our shareholders who are funding the cancer fight,” comments Mentor Capital, CEO, Chester Billingsley.

Billingsley, who first studied proton radiology at MIT, explains why he chose to fund this cancer breakthrough: “Neutrons pass harmlessly through human tissue without the collateral damage of radiation. However, if just a few atoms of Gadolinium are biologically tagged within the cancer nuclei, the absorption of a neutron ejects a high energy electron that can cleave the double DNA strand, stopping the cancer cell. This novel approach may allow for full body treatment for blood or metastasized cancers, where classic radiation would kill the patient.” Hadron Systems, Inc. reports a clinical trial to include late-stage cancer patients is planned for September 2012.
A sample of a $10 Million pro forma Direct Cancer Equity Contract, similar to the contract with Hadron, with additional relevant information, is presented at www.MentorCapital.com. Mentor Capital, Inc. targets its acquisitions and investments exclusively toward leading-edge cancer companies.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.


__________

Chet Billingsley is the CEO and Chairman of Mentor Capital, Inc. Mentor Capital, Inc. invests in leading-edge cancer companies across all companies in its proprietary Cancer Immunotherapy Index and seeks to overweight acquisition or stock purchase funding in those companies with the greatest promise.


Chet Billingsley, CEO

Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065
(760) 788-4700
(760) 788-2525 Fax

 ↑ Back to Top